Irene Olivera
Overview
Explore the profile of Irene Olivera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cirella A, Olivera I, Luri-Rey C, Bolanos E, Berraondo P, Melero I
Expert Opin Ther Targets
. 2023 Nov;
27(11):1035-1042.
PMID: 37993172
Introduction: Interleukin-18 (IL-18) is a myeloid leukocyte inflammatory mediator whose main known function is to elicit IFNγ secretion from T and NK cells. Areas Covered: This function offers potential in...
2.
Bella A, Arrizabalaga L, Di Trani C, Gonzalez-Gomariz J, Gomar C, Russo-Cabrera J, et al.
J Immunother Cancer
. 2023 Nov;
11(11).
PMID: 37918917
Background: Peritoneal carcinomatosis is an advanced stage of cancer in which the disease has spread to the peritoneal cavity. In order to restore antitumor immunity subverted by tumor cells in...
3.
Cirella A, Bolanos E, Luri-Rey C, Di Trani C, Olivera I, Gomis G, et al.
Mol Ther Nucleic Acids
. 2023 Aug;
33:668-682.
PMID: 37650116
Intratumoral immunotherapy strategies for cancer based on interleukin-12 (IL-12)-encoding cDNA and mRNA are under clinical development in combination with anti-PD-(L)1 monoclonal antibodies. To make the most of these approaches, we...
4.
Glez-Vaz J, Azpilikueta A, Ochoa M, Olivera I, Gomis G, Cirella A, et al.
Sci Adv
. 2023 Aug;
9(33):eadf6692.
PMID: 37595047
CD137 (4-1BB) is a member of the TNFR family that mediates potent T cell costimulatory signals upon ligation by CD137L or agonist monoclonal antibodies (mAbs). CD137 agonists attain immunotherapeutic antitumor...
5.
Olivera I, Luri-Rey C, Teijeira A, Eguren-Santamaria I, Gomis G, Palencia B, et al.
Clin Cancer Res
. 2023 Jul;
29(23):4711-4727.
PMID: 37522874
In cancer pathogenesis, soluble mediators are responsible for a type of inflammation that favors the progression of tumors. The mechanisms chiefly involve changes in the cellular composition of the tumor...
6.
Ochoa M, Sanchez-Gregorio S, de Andrea C, Garasa S, Alvarez M, Olivera I, et al.
Cell Rep Med
. 2023 Apr;
4(4):101009.
PMID: 37040772
Immune checkpoint-inhibitor combinations are the best therapeutic option for advanced hepatocellular carcinoma (HCC) patients, but improvements in efficacy are needed to improve response rates. We develop a multifocal HCC model...
7.
Alvarez M, Molina C, Garasa S, Ochoa M, Rodriguez-Ruiz M, Gomis G, et al.
Oncoimmunology
. 2023 Apr;
12(1):2197370.
PMID: 37035637
BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has...
8.
Olivera I, Bolanos E, Gonzalez-Gomariz J, Hervas-Stubbs S, Marino K, Luri-Rey C, et al.
Cell Rep Med
. 2023 Mar;
:100978.
PMID: 36933554
Interleukin-12 (IL-12) gene transfer enhances the therapeutic potency of adoptive T cell therapies. We previously reported that transient engineering of tumor-specific CD8 T cells with IL-12 mRNA enhanced their systemic...
9.
Di Trani C, Cirella A, Arrizabalaga L, Bella A, Fernandez-Sendin M, Russo-Cabrera J, et al.
Oncoimmunology
. 2022 Dec;
12(1):2147317.
PMID: 36531687
Previous studies have shown that local delivery of tumor antigen-specific CD8 T lymphocytes engineered to transiently express single-chain IL-12 mRNA is highly efficacious. Peritoneal dissemination of cancer is a frequent...
10.
Cirella A, Bolanos E, Di Trani C, de Andrea C, Sanchez-Gregorio S, Etxeberria I, et al.
Cancer Immunol Res
. 2022 Dec;
11(2):184-198.
PMID: 36478221
IL12-based local gene therapy of cancer constitutes an active area of clinical research using plasmids, mRNAs, and viral vectors. To improve antitumor effects, we have experimentally tested the combination of...